Valeant's (VRX) Amended Facility Expected, But Shares Remain Uninvestible - Piper
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
UPDATE: Valeant Pharma (VRX) Says Aware of T. Rowe Price Filing and Hasn't Been Served Yet
August 18, 2016 3:40 PM EDT(Updated - August 18, 2016 3:41 PM EDT)
Valeant Pharma (NYSE: VRX) announced the following on Thursday:
We are aware of the filing and have not been served yet. This T. Rowe Price complaint repeats allegations and claims as in the pending securities putative... More
Valeant's (VRX) Amended Credit Agreement Seen as Positive - Morgan Stanley
August 18, 2016 1:55 PM EDTMorgan Stanley maintained an Overweight rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $42. Earlier the company announced that it has obtained the requisite lender approval for an amendment to its credit facility. Analyst David Risinger sees the news as a positive.
"In-line with our expectations, VRX amended its credit... More
Valeant amends credit facility for second time in six months
August 18, 2016 8:37 AM EDT(Reuters) - Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) said its lenders had approved an amendment to its credit facility, giving the drugmaker more flexibility to sell assets and repay loans by taking on other debt.
The embattled... More
Valeant Pharma (VRX) Announces Lender Consent for Credit Facility Amendment
August 18, 2016 8:01 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that it has obtained the requisite lender approval for an amendment to its credit facility. The Company expects to close the amendment next week, subject to customary closing conditions. The amendment will:
reduce the interest... More
Valeant Pharma (VRX) Ramps to Session Highs Following Analyst Upgrade
August 17, 2016 12:00 PM EDTValeant Pharma (NYSE: VRX) shares are reaching new session highs midday Wednesday. The stock is up well over 13 percent with high volume.
Notably, Morgan Stanley upgraded the stock earlier. For more color on the call, click here.
... More